{"id":"W2076869933","doi":"10.1007/s40273-014-0241-z","title":"Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada","year":2014,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline; Eli Lilly and Company","keywords":"Dabrafenib; Dacarbazine; Vemurafenib; Medicine; Oncology; Progression-free survival; Internal medicine; Hazard ratio; Metastatic melanoma; Melanoma; Cancer research; Overall survival; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001505247,0.0001719196,0.0002851377,0.00006078335,0.00002498194,0.000007749091,0.000104339,0.00003080178,0.00003879235],"category_scores_gemma":[0.00003033146,0.0001414047,0.00002850199,0.00007033153,0.00002322614,0.000009845975,0.00003072748,0.0000478802,0.000003410025],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003102238,"about_ca_system_score_gemma":0.0006677825,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.2010019,"about_ca_topic_score_gemma":0.6659194,"domain_scores_codex":[0.9990448,0.0001448652,0.0002534272,0.0002831937,0.00005729895,0.00021645],"domain_scores_gemma":[0.9994602,0.0001468539,0.0001162084,0.0001559353,0.00004375734,0.00007708512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01084745,0.001258509,0.9268394,0.0003097542,0.0004907878,0.00007300181,0.0002879738,0.03186535,0.01516185,0.0001437857,0.00005751352,0.0126646],"study_design_scores_gemma":[0.02385694,0.003150652,0.2757384,0.00008657194,0.00008742387,0.00001011244,0.00007840418,0.002462333,0.692609,0.000053214,0.001396158,0.0004708229],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983977,0.00004278426,0.0001980492,0.0000167283,0.00009024542,0.0007447667,0.0001715477,0.000002221032,0.0003359725],"genre_scores_gemma":[0.9991285,0.00003033099,0.000106013,0.00008779281,0.00002196094,0.0001349802,0.0004312676,0.00002069345,0.0000384312],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6774471,"threshold_uncertainty_score":0.8043187,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01314990988160582,"score_gpt":0.2653310791335,"score_spread":0.2521811692518942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}